Takeda is Japan’s largest drug company. At the end of 2019, Takeda acquired Shire and the deal raised Takeda’s interest-bearing debt to more than $46 billion, according to the Nikkei Asian Review. In response, the drugmaker said it plans to divest $10 billion worth of its non-core operations.
Taisho Pharmaceutical, Japan’s largest over-the-counter drug company, is reportedly the leading candidate to purchase the business from Takeda.
Takeda plans to focus on developing treatments for cancer, digestive system and central nervous system diseases and rare conditions, according to the Nikkei Asian Review.
Read the full article here.
More articles on pharmacy:
CMS cleared to survey 340B hospitals on their drug acquisition costs
SSM Health to close 2 retail pharmacies
The race to develop a COVID-19 vaccine: 5 updates
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.